Evidence map›Paper›PMID 39660329›Full record

ArticleInternational journal of clinical and experimental pathology2024

Association between EPCAM upregulation and clinicopathological parameters and outcomes of breast cancer.

Nahid Nafissi, Saeed Azad Armaki, Ebrahim Babaee, Pegah Babaheidarian, Elaheh Safari, Soheila Sayad, Samine Saghafinia, Masoumeh Safaee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical and experimental pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nahid NafissiDepartment of Breast Diseases Surgery, Breast Health and Cancer Research Center, Iran University of Medical Sciences Tehran, Iran.
Saeed Azad ArmakiKhatam Hospital Tehran, Iran.
Ebrahim BabaeeDepartment of Epidemiology, Preventive Medicine and Public Health Research Center, Psychosocial Health Research Institute, Community and Family Medicine Department, School of Medicine, Breast Health and Cancer Research Center, Iran University of Medical Sciences Tehran, Iran.
Pegah BabaheidarianDepartment of Pathology, School of Medicine, Breast Health and Cancer Research Center, Iran University of Medical Sciences Tehran, Iran.
Elaheh SafariDepartment of Immunology, School of Medicine, Breast Health and Cancer Research Center, Iran University of Medical Sciences Tehran, Iran.
Soheila SayadDepartment of Surgery, Breast Health and Cancer Research Center, Iran University of Medical Sciences Tehran, Iran.
Samine SaghafiniaDepartment of Medical Education, Student Research Committee, School of Medicine, Iran University of Medical Sciences Tehran, Iran.
Masoumeh SafaeeDepartment of Surgery, School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEpCAM (epithelial cell adhesion molecule) protein expression was detected in 45 to 90% of breast cancers in different studies, and high expression levels were associated with poor outcomes in several retrospective analyses. This study aims to investigate the relationship between EpCAM and clinicopathological parameters and survival in breast cancer. METHODOLOGY: This study was conducted as a Quasi-Experimental Cohort Study to explore 100 breast cancer patients. After the surgical excision of breast cancer, pathology blocks were deparaffinized and subjected to IHC (immunohistochemistry) for EpCAM examination. Using a Roche VENTANA Benchmark GX automated staining instrument and a well-established IHC staining protocol, the expression of EpCAM in breast cancer tissue was assessed. Independent sample T-test and Chi squared and Logistic Regression test with STATA version 17 software were used for data analysis.

resultsThe difference in the distribution of the negative state of biomarkers (ER = estrogen receptor, PR = Progesterone receptor) and EPCAM positive group was significant (

conclusionWe found that Basal like breast cancer, HER2+, and stage 3 increase the chance of EpCAM positivity. It seems that EPCAM positive cancer has more chance for recurrence and metastasis.

Indexed as

Breast cancerepithelial cell adhesion moleculemetastasisrecurrencesurvival

Identifiers

PMID39660329
PMCPMC11626292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.